VILOXAZINE HYDROCHLORIDE

Details

Stereochemistry	RACEMIC
Molecular Formula	C13H19NO3.ClH
Molecular Weight	273.756
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CCOC1=C(OCC2CNCCO2)C=CC=C1

InChI

InChIKey=HJOCKFVCMLCPTP-UHFFFAOYSA-N

InChI=1S/C13H19NO3.ClH/c1-2-15-12-5-3-4-6-13(12)17-10-11-9-14-7-8-16-11;/h3-6,11,14H,2,7-10H2,1H3;1H

HIDE SMILES / InChI

Molecular Formula	C13H19NO3
Molecular Weight	237.2949
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22454923 | https://www.ncbi.nlm.nih.gov/pubmed/324751 | http://bipolarnews.org/?tag=viloxazine | https://www.ncbi.nlm.nih.gov/pubmed/30924702

Viloxazine is an antidepressant drug was used to treat patients with depression. Viloxazine inhibits noradrenaline uptake. This drug was approved in some Europe countries, but not in the USA, but then it was discontinued because of competition from other drugs. In the frame of drug repositioning, Viloxazine participated in clinical trials for the treatment of attention deficit hyperactivity disorder. Phase II of trials was successfully passed.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Sodium-dependent noradrenaline transporter 38 Target ID: P23975 Gene ID: 6530.0 Gene Symbol: SLC6A2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/27230580	Inhibitor 8297
Sodium-dependent noradrenaline transporter 38 Target ID: P23975 Gene ID: 6530.0 Gene Symbol: SLC6A2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/27230580	Inhibitor 8297

PubMed

Title	Date	PubMed
[Comparative evaluation of the therapeutic efficacy of the antidepressants adepren, linamiphen and emovit].	1986	3716711
[Apropos of atypical melancholia with Sustiva (efavirenz)].	2001 May-Jun	11488260
A high-performance liquid chromatography method with photodiode-array UV detection for therapeutic drug monitoring of the nontricyclic antidepressant drugs.	2003 Oct	14508379
Contribution of sleep research to the development of new antidepressants.	2005	16416706
The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants.	2005	16156382
Development of a solid phase extraction for 13 'new' generation antidepressants and their active metabolites for gas chromatographic-mass spectrometric analysis.	2005 Dec 9	16314157
Internet-based search of randomised trials relevant to mental health originating in the Arab world.	2005 Jul 26	16045805
Enhancing central noradrenergic function in depression: is there still a place for a new antidepressant?	2005 Mar	18568121
Gastrointestinal bleeding and massive liver damage in neuroleptic malignant syndrome.	2005 Sep	18360563
[Trazodone for the treatment of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease: a retrospective study focused on the aggression and negativism in caregiving situations].	2006 Jun	16856516
Comparison of electron and chemical ionization modes by validation of a quantitative gas chromatographic-mass spectrometric assay of new generation antidepressants and their active metabolites in plasma.	2007 Dec 28	18022628
Quantification of tricyclic antidepressants and monoamine oxidase inhibitors by high-performance liquid chromatography-tandem mass spectrometry in whole blood.	2007 May	17555643
Antidepressant drugs for narcolepsy.	2008 Jan 23	18254030
Narcolepsy: current treatment options and future approaches.	2008 Jun	18830438
A prognostic system applicable to patients with resectable liver metastasis from colorectal carcinoma staged by positron emission tomography with [18F]fluoro-2-deoxy-D-glucose: role of primary tumor variables.	2008 May	18471711
Adjustment Disorder: epidemiology, diagnosis and treatment.	2009 Jun 26	19558652
Determination of antidepressants in human postmortem blood, brain tissue, and hair using gas chromatography-mass spectrometry.	2009 Nov	18839201
Getting the balance right: Established and emerging therapies for major depressive disorders.	2010 Sep 7	20856599

Patents

Sample Use Guides

In Vivo Use Guide

100 mg

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Sat Dec 16 05:26:15 GMT 2023` Edited by `admin` on `Sat Dec 16 05:26:15 GMT 2023`
Record UNII	OQW30I1332
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

VILOXAZINE HYDROCHLORIDE

Official Name

English

VILOXAZINE HYDROCHLORIDE [USAN]

Common Name

English

Viloxazine hydrochloride [WHO-DD]

Common Name

English

2-[(O-Ethoxyphenoxy)methyl]morpholine hydrochloride

Common Name

English

SPN-812

Code

English

VILOXAZINE HYDROCHLORIDE [MART.]

Common Name

English

VILOXAZINE HCL

Common Name

English

(±)-MORPHOLINE, 2-((2-ETHOXYPHENOXY)METHYL)-, HYDROCHLORIDE

Systematic Name

English

Qelbree

Brand Name

English

VIVALAN

Brand Name

English

VILOXAZINE HYDROCHLORIDE [ORANGE BOOK]

Common Name

English

ICI-58834

Code

English

MORPHOLINE, 2-((2-ETHOXYPHENOXY)METHYL)-, HYDROCHLORIDE

Systematic Name

English

ICI 58,834

Code

English

VILOXAZINE HYDROCHLORIDE [MI]

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

2384